24 July 2018 - - Seattle, Washington-based small-molecule and protein therapeutics specialist Omeros Corp. (NASDAQ: OMER) has dosed the first cohort of subjects in its Phase 1 clinical trial, evaluating the lead phosphodiesterase 7 inhibitor in Omeros' OMS527 program broadly targeting addictions and compulsive disorders, the company said.
Inhibitors of PDE7 have been demonstrated to modulate the brain's dopamine levels, widely recognized as central to both addictive and compulsive disorders. The trial remains on track to deliver escalating single and multiple doses of the drug.
The initial target planned for OMS527 is nicotine addiction. The Phase 1 clinical trial is designed to assess the safety and pharmacokinetics of OMS527 administered in varying doses and formulations.
Completion of the Phase 1 single-ascending- and multiple-ascending-dose trial for OMS527 is expected in the first half of 2019.
Omeros is committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system.
It has multiple Phase 3 and Phase 2 clinical-stage development programs focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington's disease and cognitive impairment, and addictive and compulsive disorders.